Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Assembly Biosciences (NQ: ASMB )

14.90 +0.21 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,933
Open 14.83
Bid (Size) 13.50 (4)
Ask (Size) 15.00 (1)
Prev. Close 14.69
Today's Range 14.11 - 14.96
52wk Range 7.692 - 20.04
Shares Outstanding 52,121,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved... 
Via Benzinga
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+49.24%
+49.24%
1 Month
-5.87%
-5.87%
3 Month
+12.79%
+12.79%
6 Month
+9.24%
+9.24%
1 Year
+57.17%
+57.17%

More News

Read More
ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Insiders Buying American Software And 2 Other Stocks
Via Benzinga
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024
Via InvestorPlace
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023
Via InvestorPlace
Assembly Biosciences Announces Effective Date of Reverse Stock Split
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Provides Anticipated Development Milestones for 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.